These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

489 related items for PubMed ID: 14581437

  • 1. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.
    Coiffier B, Mounier N, Bologna S, Fermé C, Tilly H, Sonet A, Christian B, Casasnovas O, Jourdan E, Belhadj K, Herbrecht R, Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma.
    J Clin Oncol; 2003 Dec 01; 21(23):4402-6. PubMed ID: 14581437
    [Abstract] [Full Text] [Related]

  • 2. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.
    Bosly A, Sonet A, Pinkerton CR, McCowage G, Bron D, Sanz MA, Van den Berg H.
    Cancer; 2003 Sep 01; 98(5):1048-54. PubMed ID: 12942574
    [Abstract] [Full Text] [Related]

  • 3. Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma.
    Rényi I, Bárdi E, Udvardi E, Kovács G, Bartyik K, Kajtár P, Masát P, Nagy K, Galántai I, Kiss C.
    Pathol Oncol Res; 2007 Sep 01; 13(1):57-62. PubMed ID: 17387390
    [Abstract] [Full Text] [Related]

  • 4. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.
    Cortes J, Moore JO, Maziarz RT, Wetzler M, Craig M, Matous J, Luger S, Dey BR, Schiller GJ, Pham D, Abboud CN, Krishnamurthy M, Brown A, Laadem A, Seiter K.
    J Clin Oncol; 2010 Sep 20; 28(27):4207-13. PubMed ID: 20713865
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
    Knoebel RW, Lo M, Crank CW.
    J Oncol Pharm Pract; 2011 Sep 20; 17(3):147-54. PubMed ID: 20332174
    [Abstract] [Full Text] [Related]

  • 6. Single 6-mg dose of rasburicase: The experience in a large academic medical center.
    Nauffal M, Redd R, Ni J, Stone RM, DeAngelo DJ, McDonnell AM.
    J Oncol Pharm Pract; 2019 Sep 20; 25(6):1349-1356. PubMed ID: 30111244
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of recombinant urate oxidase (rasburicase) for treatment and prophylaxis of hyperuricemia in children undergoing chemotherapy.
    Pession A, Barbieri E, Santoro N, Paolucci P, Porta F, Locatelli F.
    Haematologica; 2005 Jan 20; 90(1):141-2. PubMed ID: 15642687
    [Abstract] [Full Text] [Related]

  • 8. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma.
    Pui CH, Mahmoud HH, Wiley JM, Woods GM, Leverger G, Camitta B, Hastings C, Blaney SM, Relling MV, Reaman GH.
    J Clin Oncol; 2001 Feb 01; 19(3):697-704. PubMed ID: 11157020
    [Abstract] [Full Text] [Related]

  • 9. Prevention and treatment of hyperuricemia in hematological malignancies.
    Cairo MS.
    Clin Lymphoma; 2002 Dec 01; 3 Suppl 1():S26-31. PubMed ID: 12521386
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies.
    Ribeiro RC, Pui CH.
    Clin Lymphoma; 2003 Mar 01; 3(4):225-32. PubMed ID: 12672271
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase.
    Hummel M, Reiter S, Adam K, Hehlmann R, Buchheidt D.
    Eur J Haematol; 2008 Apr 01; 80(4):331-6. PubMed ID: 18081720
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Is rasburicase needed for prevention of tumor lysis syndrome during treatment of less aggressive hematolymphoid malignancies?
    Zaidi SZ, Aljurf M.
    J Clin Oncol; 2004 Aug 15; 22(16):3430-1; author reply 3431-2. PubMed ID: 15310789
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients.
    Herrington JD, Dinh BC.
    J Oncol Pharm Pract; 2015 Apr 15; 21(2):111-7. PubMed ID: 24549060
    [Abstract] [Full Text] [Related]

  • 18. Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.
    Kennedy LD, Ajiboye VO.
    J Oncol Pharm Pract; 2010 Sep 15; 16(3):205-13. PubMed ID: 19923162
    [Abstract] [Full Text] [Related]

  • 19. A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome.
    Kikuchi A, Kigasawa H, Tsurusawa M, Kawa K, Kikuta A, Tsuchida M, Nagatoshi Y, Asami K, Horibe K, Makimoto A, Tsukimoto I.
    Int J Hematol; 2009 Nov 15; 90(4):492-500. PubMed ID: 19701676
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis.
    Feng X, Dong K, Pham D, Pence S, Inciardi J, Bhutada NS.
    J Clin Pharm Ther; 2013 Aug 15; 38(4):301-8. PubMed ID: 23550846
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.